Abstract:Poly (ADP-ribose) polymerases (PARP) are a family of nuclear protein enzymes involved in the DNA damage response. The role of PARP-1 in base excisional repair has been extensively characterized. More recent in vitro studies additionally implicate a role for PARP-1 in facilitating homologous recombination and nonhomologous end-joining. The more faithful process of homologous recombination repair of double-stranded DNA breaks involves localization of BRCA-1 and BRCA-2 to sites of DNA damage, resection of the double-stranded break, and gap-filling DNA synthesis using the homologous sister chromatid as a template. Simultaneous dysfunction of both DNA repair pathways decreases the ability of cells to compensate, and forms the basis for the concept of synthetic lethality. Treatment strategies, thus far, have focused on two main principles: (i) exploitation of the concept of synthetic lethality in homologous recombination-deficient tumors, primarily in breast and ovarian cancer patients with BRCA mutation, and (ii) as radiosensitizers and chemosensitizers. BRCA deficiency accounts for only a fraction of dysfunction in homologous recombination repair. Epigenetic alterations of BRCA function and defects within the Fanconi anemia pathway also result in defective DNA repair. Rational therapeutic combinations exploiting alternate mechanisms of defective DNA repair, abrogation of cell-cycle checkpoints, and additional functions of PARP-1 present novel opportunities for further clinical development of PARP inhibitors. On the basis of the results of clinical studies of PARP inhibitors thus far, it is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting.

PARP2 controls double-strand break repair pathway choice by limiting 53BP1 accumulation at DNA damage sites and promoting end-resection

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

Role of 53BP1 in end protection and DNA synthesis at DNA breaks

XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites

The CSB chromatin remodeler regulates PARP1- and PARP2-mediated single-strand break repair at actively transcribed DNA regions

The dynamics and Regulation of PARP1 and PARP2 in response to DNA damage and during replication

PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends

Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks

53BP1: a DSB escort

The FHA and BRCT Domains Recognize ADP-ribosylation During DNA Damage Response.

53BP1 Protects Against CtIP-Dependent Capture of Ectopic Chromosomal Sequences at the Junction of Distant Double-Strand Breaks.

Structural dynamics of DNA strand break sensing by PARP-1 at a single-molecule level

Poly(ADP‐ribose) Polymerase‐1 Promotes Recruitment of Meiotic Recombination‐11 to Chromatin and DNA Double‐strand Break Repair in Ku70‐deficient Breast Cancer Cells

Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair

Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection

Temporal dynamics of base excision/single-strand break repair protein complex assembly/disassembly are modulated by the PARP/NAD+/SIRT6 axis

PARP1-dependent DNA-protein crosslink repair

Molecular Pathways: Targeting PARP in Cancer Treatment

PARP1 is a TRF2-associated Poly(adp-Ribose)polymerase and Protects Eroded Telomeres.